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Background: Serum hepatitis C virus (HCV) RNA levels and genotypes are considered to be important determinants 
of the response to interferon treatment. Generally, patterns of viral loads have been reported for HCV type 1 
infections and categorized as low- or high-level viremia. We studied the distribution of HCV RNA levels in patients 
predominantly infected with HCV type 3 and correlated it with hepatic damage. 
Methods: Serum HCV RNA levels and HCV serotypes were determined in 245 anti-HCV-positive patients repre- 
senting all the major ethnic groups of Pakistan. Patients were grouped according to their HCV RNA levels as: level 
I (up to 50th percentile); level II (50th to 75th percentile); and level III (>75th percentile). 
Results: Sixty-one patients (25%) had high-level viremia (level III) of 13.9 mega equivalent per milliliter (MEq/mL) 
or greater. These were more likely to be males (48 versus 13, PcO.05). A higher viral load correlated with advanced 
levels of fatty changes in liver. HCV type 3 was found in 68% of the samples, and type 1 in 14%; the rest were 
undefined. Mean HCV RNA levels were lower in patients infected with HCV type 3 than in patients infected with 
HCV type 1 (8.63 MEq/mL versus 37 MEq/mL; P<O.OOl). 
Conclusions: Most patients with HCV type 3 infection had viremia that was significantly lower than that in HCV 
type l-infected patients. This may be the reason for the better response to treatment usually seen in such cases. The 
severity of histologic changes was not associated with HCV type 3 viremia levels. 
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INTRODUCTION 
Approximately 3 % of the world’s population is infected 
with hepatitis C virus (HCV), with an estimated 170 
million carriers globally, most of whom reside in the 
developing wor1d.i HCV is a major cause of morbidity 
and mortality in Pakistan.2 Local studies have revealed 
an HCV antibody seroprevalence rate of 1.2-2.4% in 
volunteer blood donors3 and up to 6% in some com- 
munities in the countiy4 
Based on variations in HCV RNA, six major geno- 
types and several subtypes have been defined.5 Initial 
studies from Pakistan suggest that HCV type 3 is the 
predominant genotype in the country, being present in 
nearly 80% of HCV-infected patients.‘j 
Response to interferon (IFN-(x) treatment is prim- 
arily linked to pretreatment serum HCV RNA levels 
and genotypes.’ Though the pathogenic significance of 
HCV genotypes is not clearly understood, genotypes 
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such as types 2 and 3 have shown a better response to 
IFN treatment.* The biological reasons for these obser- 
vations are still unclear. Many studies have documented 
HCV quantification data for type 1, and, based on those 
studies, HCV viral load is arbitrarily categorized as low- 
level (~3 million copies/ml) or high-level viremia (>3 
million copies/mL).8 Little is known about the distri- 
bution of HCV RNA titers in populations predomi- 
nantly infected with genotype 3, and its relationship 
with markers of liver disease, e.g. severity of histologic 
changes. 
This study was conducted to determine the distri- 
bution of viral load in a population of patients pre- 
dominantly infected with HCV type 3, and possible 
associations between the magnitude of viremia and histo- 
pathologic changes in liver were also examined. 
PATIENTS AND METHODS 
Patient population 
This study presents demographic, biochemical and viro- 
logy data of 245 HCV-positive patients representing all 
the major ethnic groups of Pakistan. All the patients 
had well-documented hepatitis C infection, as confirmed 
by clinical and laboratory findings. The liver histopatho- 
logy data were available for 53 HCV serotype 3-positive 
patients. 
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Laboratory tests RESULTS 
The alanine aminotransferase (ALT) level was deter- 
mined by an automated method (Synchron-CX-7, 
Beckman Coulter Inc., Brea, CA, USA) and expressed 
in international units (IU) per liter. Antibody to HCV 
was detected with an HCV microparticle enzyme im- 
munoassay (MEIA) third-generation kit, according to the 
manufacturer’s instructions (Abbott, Chicago, IL, USA). 
Hepatitis C virus RNA screening and quantification 
The study subjects comprised 161 males and 84 females, 
with a mean age of 39 years (range 11-64 years). The 
selected subjects represented all the major ethnic groups 
of Pakistan. All of the patients were positive for anti- 
HCV antibody and viral RNA. Their mean+SEM ALT 
level was 94k6.6 IU/L, and ranged between 18 and 
-411 IU/L. Of 245 patients, only 53 patients were both 
serotype 3 positive and had liver histopathology findings 
available for association analysis. 
The Amplicor HCV RNA assay (Roche Molecular Sys- 
tems, Branchburg, NJ, USA) was used to detect HCV 
RNA in patients’ sera. The Quantiplex HCV RNA 
2.0 bDNA assay (Chiron Corporation, Emeryville, CA, 
USA) was used for quantification of HCV RNA in 
serum according to the manufacturer’s instructions. The 
minimum quantification limit of the assay was 0.2 
MEq/mL, equivalent to 200 000 HCV RNA copies per 
milliliter of serum. 
Hepatitis C virus serotyping 
HCV serotypes were determined using the Murex HCV 
serotyping l-6 assay, according to the manufacturer’s 
instructions (Murex Biotech, Dartford, UK).The Murex 
HCV serotyping l-6 assay is based on an immune 
response to the NS4 protein of HCV, which has been 
shown to vary at the amino acid level among HCV 
‘genotypes’.9 The differential response of antisera to the 
regions of NS4 is measured in an ELISA format. 
The viral titers showed a wide range of distribution, 
from 0.2 to 79.5 MEq/mL, with a mean+SEM of 
10.6?1.0 MEq/mL. For the purpose of analysis, RNA 
values were arbitrarily categorized into three levels: 
viral titers in level I (low; titers up to the 50th percentile) 
ranged between 0.2 and 3.0 MEq/mL; viral titers in level 
II (medium; titers between the 50th and 75th percentiles) 
ranged from 3.1 to 13 MEq/mL; and all those having 
titers above 13 MEq/mL were categorized as level III 
(high; titer above the 75th percentile).The mean+SEM 
titers for levels I, II and III were 1.1?0.07,7.4?0.4 and 
33.2k2.3, respectively (Table l).There was no difference 
in mean age among the three levels of viremia. How- 
ever, in the high-level viremia group, there were signifi- 
cantly more males than females (PcO.05). 
Liver histology 
Specimens for liver biopsy were stained with hema- 
toxylin-eosin, reticulin, periodic acid Schiff (PAS), PAS 
diastase, and Masson’s trichrome. Histologic activity was 
assessed using the Scheuer grading system.r” In addition, 
lobular steatosis, portal lymphoid aggregates, Kupffer 
cells or lymphocyte aggregates and bile duct epithelial 
damage were also evaluated. 
With the Murex HCV serotyping l-6 assay, HCV 
type 3 was found in 68% (167/245) of the patients, 
whereas type 1 was identified in only 14% (34/245) of 
the patients. HCV serotypes in 18% (44/245) of HCV 
RNA-positive samples remained undetermined by the 
Murex assay. These samples, when analyzed by HCV 
Western blot assay (Murex Biotech), indicated that 
these patients had not developed antibody to NS4- 
region peptides. The 25th and 50th percentile HCV 
RNA values of patients with HCV type 3 infections 
were 0.4 and 3.15 MEq/mL, respectively. Though not 
statistically significant, the mean ALT level was slightly 
higher in HCV type l-infected patients. Moreover, mean 
HCV RNA levels were significantly higher in patients 
infected with HCV type 1 than in patients infected with 
HCV type 3 (37 versus 8.6 MEq/mL;P<O.OOl;Figure 1). 
Statistical analysis 
All results are expressed as mean f standard error of 
mean (SEM). Differences in virologic, biochemical or 
demographic features between groups were analyzed 
using Student’s t-test. For all tests, a two-tailed P-value 
of ~0.05 was considered to be significant. 
A comparison of histologic features.and serum HCV 
RNA level is presented in Table 2. Our findings failed to 
demonstrate a statistically significant association between 
hepatic inflammation and fibrosis, and serum HCV RNA 
levels, in HCV type 3-infected patients. Patients with 
moderate-to-severe steatosis exhibited higher mean 
RNA levels (10.5 MEq/mL) than patients diagnosed with 
Table 1. Classification of hepatitis C patients according to their HCV RNA levels 
Level N Male/female Mean age (years) 
Viral load 
(meankSEM) 
ALT (IUlmL) 
(mean?SEM) 
I 123 76147 39 1 .I 20.07 8527.6 
II 61 37124 39 7.420.4 12Ok18 
III 61 4811 3a 41.7 33.222.3 82k8.9 
aMale-to-female ratio was significantly different in level III (P~0.05). 
274 International Journal of Infectious Diseases I Volume 6, Number 4,2002 
50 
40 
zi- 
E 
B 
g 30 
E .z 
p 20 
5 
10 
0 
m Type 1 Type 3 
Viral load ALT levels 
Figure 1. Comparison of mean viral titers and ALT levels 
between groups of patients infected with HCV type 1 or HCV 
type 3. *HCV RNA levels of patients infected with type 1 are 
significantly higher than those observed in patients infected 
with HCV type 3 (P-=0.05), whereas the distribution of ALT 
levels between the two groups is not statistically different 
(see text for details). 
mild steatosis (RNA levels 7.10 MEq/mL). However, 
this difference was not statistically significant. Most of 
the patients at the time of diagnosis had moderate- to 
high-level inflammation and fibrosis. Stage 4 liver damage 
was seen in 20.75%, and grade 4 inflammation was 
observed in 3.77%. Mild-to-moderate fatty changes in 
liver and sinusoidal activation were recognized in almost 
85% of the patients. Mild changes were present in 
47.16%, moderate changes in 17%, and marked fatty 
changes in 18.86%. In addition, bile duct damage and 
lymphoid aggregates were seen in 90% of all the liver 
biopsies examined. 
DISCUSSION 
Among all types of viral hepatitis diagnosed in the local 
community, HCV is responsible for up to 56% of the 
total cases.2 Regional differences in the prevalence of 
HCV are highlighted by many studies. For example, a 
study from northern Pakistan demonstrated HCV anti- 
bodies in 77% of individuals suspected of having viral 
hepatitis.” Pasha et al, in a community-based study, 
showed an exceptionally high prevalence of HCV anti- 
bodies (6%) among randomly selected healthy indi- 
viduals from the city of Hafizabad in the Punjab pro- 
vince.4 Moreover, high anti-HCV positivity (70%) was 
reported in multiply transfused thalassemic children.12 
Our study demonstrates that the major HCV serotype 
in Pakistan is type 3; so the regional differences in HCV 
seroprevalence cannot be explained on the basis of 
differences in genotype distribution. 
The current literature indicates that genotype 
determination provides clinically relevant information. 
Different types and/or subtypes of HCV infection are 
associated with different geographic distributions, routes 
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Table 2. Correlation between severity of liver damage and 
serum HCV RNA levels 
Liver damage Patients Serum /-KY RNA 
criteria N (%) (mean (MEqImL)) 
Stage 0 9 (16.98) 10.04 
1 12 (22.64) 9.86 
2 10 (18.86) 14.73 
3 11 (20.75) 6.15 
4 11 (20.75) 7.38 
Grade 0 3 (5.56) 1.79 
1 9 (16.98) 6.06 
2 20 (37.73) 10.18 
3 19 (35.84) 10.98 
4 2 (3.77) 8.55 
Fatty changes 0 9 (16.98) 7.10 
1 25 (47.16) 9.87 
2 9 (16.98) 8.68 
3 10 (18.86) 10.53 
Total number of patients=53. 
of transmission, and responses to interferon treat- 
ment.5,13 HCV genotype 3 is endemic in Southeast Asian 
countries, but it is also found in other regions of the 
world.5 Several studies have indicated that infection 
with certain HCV genotypes is influenced by the route 
of its transmission. For instance, Pawlotsky et al demon- 
strated that genotype la was the major genotype in 
patients receiving multiple transfusions, while genotype 
3a was detected primarily in intravenous drug users.14 
In most parts of Europe and also in the USA, type 3 
infection is found predominantly in younger patients, 
particularly in intravenous drug abusers.14 In our study, 
data regarding route of transmission were not available, 
so it was not possible to associate HCV genotype with 
route of transmission. It would be interesting to explore 
such relationships in the Pakistani population. 
HCV genotype and viral load are considered to be 
important factors in predicting response to interferon 
therapy. The evidence clearly indicates that genotype 1 
is associated with a poor response, whereas type 2 and 
3 infections have favorable responses to interferon 
therapy.15 Pretreatment HCV RNA levels are useful in 
formulating appropriate interferon dosages and durations 
of treatment. For instance, in patients infected with type 
1 HCV, serum HCV RNA values of >3 million copies/ 
mL are considered to be high titers, and merit considera- 
tion of longer courses of interferon compared to 
patients with <3 million copies of HCV RNA/mL, who 
are considered to have low-level viremia and who could 
be treated for only 6 months.* A similar distribution of 
HCV RNA titers has not been reported in populations 
where HCV type 3 is most prevalent, such as Pakistan.6 
In the present study, we have measured HCV RNA in a 
patient population predominantly infected with HCV 
type 3, using the bDNA version 2.0 assay, which has 
multiple probes and is optimized to equally quantify all 
HCV genotypes. l6 Our data show that the majority of 
the patients with HCV type 3 infection had low levels of 
viremia (53 million copies/ml), if the same cutoff is 
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used as for type l-infected patients. HCV RNA levels in 
the small number of HCV type l-infected patients in our 
study were significantly higher than in the HCV type 3- 
infected patients. This was in contrast to studies that 
have shown a random distribution of HCV RNA levels 
among patients infected with different genotypes.17 This 
finding could in part explain the substantially better 
interferon therapy response seen in Pakistani patients 
(Hamid, unpublished data). 
The correlation between HCV genotypes and 
severity of hepatitis continues to be debated.‘“,19 Portal 
lymphoid aggregates and bile duct damage are the two 
most characteristic findings in HCV infection. In this 
study, portal lymphoid aggregates were seen in 90.56% 
of cases; this is higher than the figure reported for 
Western populations. 20-23 The presence of lymphoid 
aggregates in HCV infection probably represents an 
ongoing immunologic process also seen in chronic HBV 
infection, but usually less advanced.20-23 Similarly, fatty 
changes were seen in a higher proportion of patients 
(83%) than in Western reports, suggesting fatty changes 
ranging between 31% and 72% of HCV-infected patients 
(Table 3). According to Lefkowitch et al, the higher the 
grade of large-droplet fatty change, the more likely it is 
that the patient had an HCV infection.20 In our study, 
35.4% of cases had moderate-to-marked (grade 2 or 
3) large-droplet fatty change. This tends to support the 
theory that HCV has some direct cytopathic effect on 
lymphocytes.24 Our study has not demonstrated an 
association between viral titers and the severity of 
histopathologic changes in liver, such as activity and 
fibrosis. Although higher mean viral RNA levels were 
found to be associated with advanced fatty changes, this 
trend was not statistically significant. However, no 
correlation was seen between ALT levels and viral 
load or ALT levels and HCV serotypes, suggesting that 
biochemical changes do not usually concur with histo- 
logic changes in chronic HCV infection. Additionally, no 
correlation was found between the amount of HCV 
RNA and patient’s age. Our demographic data indicate 
that there were more males than females in the high- 
viremia group (level III), and this ratio was statistically 
different when compared with the male/female ratio in 
either the level I group or the level II group. The reason 
for this finding remains unknown, and needs further 
investigation. However, this is probably consistent with 
the suggestion that women in general have a better 
response to interferon. 
In summary, we have shown the distribution of 
HCV RNA levels in a patient population infected pre- 
dominantly with HCV type 3. Patients infected with 
HCV type 3 had significantly lower RNA levels than 
HCV type l-infected patients. Most HCV type 3-infected 
patients had RNA levels equal to or less than 3 MEq/ 
mL, which may be a reason for the better response to 
treatment seen in such patients. Patients with high-level 
viremia were predominantly males. Finally, no associ- 
ation between higher HCV RNA levels and histopatho- 
logic changes was observed in this cohort. 
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